Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026)

Gilead Sciences (GILD) reported Income towards Parent Company of $2.0 billion for Q1 2026, up 53.69% on a YoY basis from $1.3 billion in Q1 2025, and down 20.06% quarter-over-quarter from $2.5 billion in Q4 2025.

Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026) Analysis & Trends

Gilead Sciences has reported Income towards Parent Company for 18 years, with the latest figure at $2.0 billion in Q1 2026.

  • For the quarter ending Q1 2026, Income towards Parent Company rose 53.69% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $9.6 billion (up 60.3% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
  • Income towards Parent Company for Q1 2026 stood at $2.0 billion, down from $2.5 billion in the prior quarter.
  • The five-year high for Income towards Parent Company was $3.1 billion in Q3 2025, with the low at -$4.2 billion in Q1 2024.
  • Historically, Income towards Parent Company has averaged $1.3 billion across 5 years, with a median of $1.6 billion in 2024.
  • Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 8100.0% — and 2024, when it slumped 523.88%.
  • Gilead Sciences' Income towards Parent Company stood at $1.6 billion in 2022, then dropped by 13.29% to $1.4 billion in 2023, then advanced by 25.85% to $1.8 billion in 2024, then soared by 41.86% to $2.5 billion in 2025, then dropped by 20.06% to $2.0 billion in 2026.
  • The last three Income towards Parent Company figures came in at $2.0 billion (Q1 2026), $2.5 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 2.02 Bn
Dec 31, 2025 2.53 Bn
Sep 30, 2025 3.05 Bn
Jun 30, 2025 1.96 Bn
Mar 31, 2025 1.32 Bn
Dec 31, 2024 1.78 Bn
Sep 30, 2024 1.25 Bn
Jun 30, 2024 1.62 Bn
Mar 31, 2024 -4.17 Bn
Dec 31, 2023 1.42 Bn
Sep 30, 2023 2.17 Bn
Jun 30, 2023 1.04 Bn
Mar 31, 2023 984.00 Mn
Dec 31, 2022 1.63 Bn
Sep 30, 2022 1.79 Bn
Jun 30, 2022 1.14 Bn
Mar 31, 2022 12.00 Mn
Dec 31, 2021 376.00 Mn
Sep 30, 2021 2.59 Bn
Jun 30, 2021 1.51 Bn